On the Same NGS Report, Why Experts Disagree
The data can be the same; the interpretation often is not. A look at why two experts can read a single genomic report and reach different conclusions, and why that is not as big a problem as it appears.
One of the most common questions in molecular oncology is how two experts can look at the same NGS report and arrive at different conclusions.
The answer is surprisingly simple: genomic testing produces data, but clinical interpretation produces a decision. The former is largely objective; the latter involves judgment. Modern sequencing platforms are impressively reliable at identifying genomic alterations. Determining what those alterations mean for a specific patient is far more complex, and that is where expert opinions diverge.
Genomic sequencing is becoming increasingly standardized. Genomic interpretation is not. The same report can support more than one reasonable conclusion.
NGS reports do not make the decision.
An NGS report can tell us a great deal about a tumor's genomic status. What it can tell us is concrete:
- what alterations are present
- variant allele frequency (VAF)
- biomarker status
- possible treatment associations
What it cannot tell us is the one question that actually matters clinically:
“What should we do for this patient today?”
That question requires interpretation, and interpretation carries uncertainty.
Five reasons experts disagree on the same evidence
When two reviewers reach different conclusions, the disagreement almost always traces back to one of five sources, and rarely to the data itself.
1They may disagree about the biology
Not every mutation drives a tumor. Some alterations are true drivers, some are passengers, and some may represent emerging resistant clones. The same alteration can be read differently depending on how significant the reviewer judges it to be to the tumor's biology. The first disagreement is often not even about treatment, it concerns what is actually driving the cancer.
2They may weigh the evidence differently
Two experts can agree that a biomarker is potentially actionable and still disagree about what to do next, because not all evidence carries the same weight. One may prioritize prospective trials, regulatory approvals, and guideline-supported indications. Another may be more open to weighing small studies, retrospective data, biological rationale, and off-label opportunities. The disagreement here is about evidence quality rather than biology.
3They may see risk differently
Every recommendation carries uncertainty. Some clinicians are comfortable pursuing a biologically plausible but weakly supported option; others prefer to stay closer to established standards of care. Neither approach is automatically right or wrong, the difference reflects how much uncertainty each expert is willing to accept.
4They may focus on different time horizons
One expert may ask what the best treatment is right now. Another may ask what preserves the most options in the future. These are not always the same thing, and treatment sequencing is one of the most common reasons experienced molecular oncologists disagree.
5They may see different missing pieces
Sometimes the disagreement does not come from the data itself, but from what is missing. One reviewer may consider the report sufficient; another may ask:
- whether RNA sequencing should be performed
- whether a repeat biopsy is needed
- whether a finding might represent clonal hematopoiesis (CHIP)
- whether germline testing is required
- whether tumor evolution has changed the biology since the original sample
Different assumptions about missing information lead to different conclusions.
Why disagreement is not necessarily a problem
Many people assume that disagreement means one expert is right and the other is wrong. In reality, molecular oncology often operates in areas where certainty does not exist. The most important question is not whether every expert agrees, but whether the reasoning can be explained.
Good molecular interpretation is transparent.
It shows which assumptions were made, what evidence was used, where the uncertainty lies, and why a recommendation was chosen. A recommendation should be understandable, not merely accepted.
The role of a structured second opinion
A second opinion is not valuable because it always changes the outcome. It is valuable because it makes the reasoning visible.
- Sometimes it confirms the original interpretation.
- Sometimes it identifies an overlooked opportunity.
- Sometimes it surfaces a hidden limitation.
In every case the goal is the same: to ensure that an important treatment decision rests on the strongest possible interpretation of the available data.
Precision oncology's reality
Genomic sequencing is becoming increasingly standardized. Genomic interpretation is not. The same report can support more than one reasonable conclusion.
What matters is not whether experts agree, but whether the reasoning behind a recommendation is biologically sound, evidence-based, and appropriate for the patient in front of us.
That is why precision oncology remains both a science and a clinical judgment.
This content is for educational purposes only. It does not constitute individual medical advice and does not replace the judgment of the treating physician.
Submit a case for expert molecular review
NGS Advisory reviews your existing NGS report against current guidelines, clarifies the exact variant and its actionability for your tumor type, and delivers a structured, calibrated second opinion.